Barclays PLC Repligen Corp Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Repligen Corp stock. As of the latest transaction made, Barclays PLC holds 26,395 shares of RGEN stock, worth $3.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,395

Previous 87,156 69.72%

Holding current value

$3.29 Million

Previous $11 Million 64.25%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$119.79 - $167.35 $7.28 Million - $10.2 Million	-60,761 Reduced 69.72%	26,395 $3.93 Million
Q2 2024 Aug 14, 2024	SELL	$120.0 - $182.95 $5.09 Million - $7.76 Million	-42,395 Reduced 32.72%	87,156 $11 Million
Q1 2024 May 15, 2024	BUY	$170.78 - $208.42 $2.63 Million - $3.21 Million	15,380 Added 13.47%	129,551 $23.8 Million
Q4 2023 Feb 15, 2024	BUY	$114.17 - $185.35 $4.2 Million - $6.82 Million	36,810 Added 47.58%	114,171 $20.5 Million
Q3 2023 Nov 07, 2023	SELL	$138.78 - $176.51 $976,317 - $1.24 Million	-7,035 Reduced 8.34%	77,361 $12.3 Million
Q2 2023 Aug 03, 2023	BUY	$138.42 - $180.31 $808,095 - $1.05 Million	5,838 Added 7.43%	84,396 $11.9 Million
Q1 2023 May 04, 2023	BUY	$154.26 - $198.1 $4.53 Million - $5.82 Million	29,387 Added 59.76%	78,558 $13.2 Million
Q4 2022 Feb 13, 2023	BUY	$162.42 - $220.56 $3.67 Million - $4.98 Million	22,591 Added 84.99%	49,171 $8.33 Million
Q3 2022 Nov 03, 2022	BUY	$160.42 - $256.21 $350,998 - $560,587	2,188 Added 8.97%	26,580 $4.98 Million
Q2 2022 Aug 12, 2022	BUY	$140.68 - $188.02 $1.41 Million - $1.88 Million	10,024 Added 69.77%	24,392 $3.96 Million
Q1 2022 May 16, 2022	BUY	$161.19 - $257.96 $188,269 - $301,297	1,168 Added 8.85%	14,368 $2.7 Million
Q4 2021 Feb 14, 2022	SELL	$247.59 - $304.47 $5.69 Million - $6.99 Million	-22,974 Reduced 63.51%	13,200 $3.5 Million
Q3 2021 Nov 09, 2021	SELL	$194.77 - $324.21 $581,972 - $968,739	-2,988 Reduced 7.63%	36,174 $10.5 Million
Q2 2021 Aug 13, 2021	BUY	$165.87 - $220.95 $3.74 Million - $4.99 Million	22,565 Added 135.96%	39,162 $7.82 Million
Q1 2021 May 13, 2021	SELL	$180.37 - $226.26 $4.78 Million - $6 Million	-26,505 Reduced 61.49%	16,597 $3.23 Million
Q4 2020 Feb 11, 2021	BUY	$148.08 - $206.57 $860,789 - $1.2 Million	5,813 Added 15.59%	43,102 $8.26 Million
Q3 2020 Nov 12, 2020	SELL	$122.51 - $158.27 $1.52 Million - $1.96 Million	-12,386 Reduced 24.93%	37,289 $5.5 Million
Q2 2020 Aug 12, 2020	BUY	$94.33 - $140.48 $7,735 - $11,519	82 Added 0.17%	49,675 $6.14 Million
Q1 2020 May 13, 2020	SELL	$84.96 - $109.14 $2.38 Million - $3.06 Million	-28,012 Reduced 36.1%	49,593 $4.79 Million
Q4 2019 Feb 10, 2020	BUY	$73.84 - $93.08 $3.16 Million - $3.99 Million	42,843 Added 123.25%	77,605 $7.18 Million
Q3 2019 Nov 14, 2019	SELL	$76.65 - $95.51 $1.38 Million - $1.72 Million	-18,039 Reduced 34.16%	34,762 $2.67 Million
Q2 2019 Aug 14, 2019	BUY	$54.2 - $85.95 $1.08 Million - $1.71 Million	19,917 Added 60.57%	52,801 $4.54 Million
Q1 2019 May 15, 2019	BUY	$49.45 - $62.8 $628,163 - $797,748	12,703 Added 62.95%	32,884 $1.94 Million
Q4 2018 Feb 14, 2019	SELL	$48.26 - $68.88 $1.2 Million - $1.71 Million	-24,791 Reduced 55.13%	20,181 $1.06 Million
Q3 2018 Nov 14, 2018	BUY	$46.8 - $58.97 $1.37 Million - $1.73 Million	29,318 Added 187.29%	44,972 $2.49 Million
Q2 2018 Aug 14, 2018	BUY	$35.26 - $47.04 $61,317 - $81,802	1,739 Added 12.5%	15,654 $736,000
Q1 2018 May 15, 2018	BUY	$30.92 - $37.27 $245,783 - $296,259	7,949 Added 133.24%	13,915 $504,000
Q4 2017 Feb 14, 2018	BUY	$32.53 - $38.92 $7,156 - $8,562	220 Added 3.83%	5,966 $216,000
Q3 2017 Nov 14, 2017	BUY	$36.98 - $46.06 $212,487 - $264,660	5,746	5,746 $219,000

Others Institutions Holding RGEN

# of Institutions

487

Shares Held

54.4M

Call Options Held

341K

Put Options Held

235K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $6.92B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account